daily oral glp-1 receptor agonist orforglipron for adults with obesity A new option is now part of medicine. FDA approved Foundayo (orforglipron), a once-daily oral GLP-1 agonist, obesity or overweight with at least one weight-related Oral GLP-1-Based Therapeutics in the
Description
Int J Mol Sci (2019) 20:5407
Less stress
(2021, June 4)
doi: 10.1016/j.neuropharm.2017.11.048 228 ParkJSKamTILeeSParkHOhYKwonSHet al
and received royalties from Medtronic
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
